Biostar Pharma Q3 sales up 29.7%
Biostar Pharma has posted a net income of $3.43m for the third quarter 2010, or $0.13 per diluted share, compared to net income of $3.13m, or $0.13 per
Summit Therapeutics’ partner Akeso has secured China’s National Medical Products Administration (NMPA) authorisation for the use of ivonescimab in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer (NSCLC) patients.